

# Impact of COVID-19 Outbreak on Pulmonary Fibrosis Drug, Global Market Research Report 2020

<https://marketpublishers.com/r/I02519761AE0EN.html>

Date: July 2020

Pages: 98

Price: US\$ 2,900.00 (Single User License)

ID: I02519761AE0EN

## Abstracts

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Pulmonary Fibrosis Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyzes the impact of Coronavirus COVID-19 on the Pulmonary Fibrosis Drug industry.

Segment by Type, the Pulmonary Fibrosis Drug market is segmented into

Pirfenidone

Nintedanib

Segment by Application

Hospital

Clinic

### Global Pulmonary Fibrosis Drug Market: Regional Analysis

The Pulmonary Fibrosis Drug market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.

The key regions covered in the Pulmonary Fibrosis Drug market report are:

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

## Global Pulmonary Fibrosis Drug Market: Competitive Analysis

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by

knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Pulmonary Fibrosis Drug market include:

Boehringer Ingelheim

Roche

FibroGen, Inc.

Merck & Co., Inc.

Bristol-Myers Squibb Company

MediciNova, Inc.

Genentech, Inc.

Cipla Inc.

Biogen

Galapagos NV

## Contents

### **1 PULMONARY FIBROSIS DRUG MARKET OVERVIEW**

- 1.1 Product Overview and Scope of Pulmonary Fibrosis Drug
- 1.2 Covid-19 Impact on Pulmonary Fibrosis Drug Segment by Type
  - 1.2.1 Global Pulmonary Fibrosis Drug Sales Growth Rate Comparison by Type (2021-2026)
  - 1.2.2 Pirfenidone
  - 1.2.3 Nintedanib
- 1.3 Covid-19 Impact on Pulmonary Fibrosis Drug Segment by Application
  - 1.3.1 Pulmonary Fibrosis Drug Sales Comparison by Application: 2020 VS 2026
  - 1.3.2 Hospital
  - 1.3.3 Clinic
- 1.4 Covid-19 Impact on Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts
  - 1.4.1 Global Pulmonary Fibrosis Drug Revenue 2015-2026
  - 1.4.2 Global Pulmonary Fibrosis Drug Sales 2015-2026
  - 1.4.3 Pulmonary Fibrosis Drug Market Size by Region: 2020 Versus 2026
- 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
  - 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
  - 1.5.2 Covid-19 Impact: Commodity Prices Indices
  - 1.5.3 Covid-19 Impact: Global Major Government Policy
- 1.6 The Covid-19 Impact on Pulmonary Fibrosis Drug Industry
- 1.7 COVID-19 Impact: Pulmonary Fibrosis Drug Market Trends

### **2 COVID-19 IMPACT ON GLOBAL PULMONARY FIBROSIS DRUG MARKET COMPETITION BY MANUFACTURERS**

- 2.1 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2015-2020)
- 2.2 Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2015-2020)
- 2.3 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2015-2020)
- 2.4 Manufacturers Pulmonary Fibrosis Drug Manufacturing Sites, Area Served, Product Type
- 2.5 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
  - 2.5.1 Pulmonary Fibrosis Drug Market Concentration Rate
  - 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
  - 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

2.7 Primary Interviews with Key Pulmonary Fibrosis Drug Players (Opinion Leaders)

### **3 COVID-19 IMPACT ON PULMONARY FIBROSIS DRUG RETROSPECTIVE MARKET SCENARIO BY REGION**

3.1 Global Pulmonary Fibrosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020

3.2 Global Pulmonary Fibrosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3.3 North America Pulmonary Fibrosis Drug Market Facts & Figures by Country

3.3.1 North America Pulmonary Fibrosis Drug Sales by Country

3.3.2 North America Pulmonary Fibrosis Drug Sales by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe Pulmonary Fibrosis Drug Market Facts & Figures by Country

3.4.1 Europe Pulmonary Fibrosis Drug Sales by Country

3.4.2 Europe Pulmonary Fibrosis Drug Sales by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Pulmonary Fibrosis Drug Market Facts & Figures by Region

3.5.1 Asia Pacific Pulmonary Fibrosis Drug Sales by Region

3.5.2 Asia Pacific Pulmonary Fibrosis Drug Sales by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America Pulmonary Fibrosis Drug Market Facts & Figures by Country

3.6.1 Latin America Pulmonary Fibrosis Drug Sales by Country

3.6.2 Latin America Pulmonary Fibrosis Drug Sales by Country

3.6.3 Mexico

3.6.3 Brazil

3.6.3 Argentina

3.7 Middle East and Africa Pulmonary Fibrosis Drug Market Facts & Figures by Country

3.7.1 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country

3.7.2 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 U.A.E

## **4 COVID-19 IMPACT ON GLOBAL PULMONARY FIBROSIS DRUG HISTORIC MARKET ANALYSIS BY TYPE**

4.1 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)

4.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2015-2020)

4.3 Global Pulmonary Fibrosis Drug Price Market Share by Type (2015-2020)

4.4 Global Pulmonary Fibrosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

## **5 COVID-19 IMPACT ON GLOBAL PULMONARY FIBROSIS DRUG HISTORIC MARKET ANALYSIS BY APPLICATION**

5.1 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)

5.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2015-2020)

5.3 Global Pulmonary Fibrosis Drug Price by Application (2015-2020)

## **6 COMPANY PROFILES AND KEY FIGURES IN PULMONARY FIBROSIS DRUG BUSINESS**

6.1 Boehringer Ingelheim

6.1.1 Corporation Information

6.1.2 Boehringer Ingelheim Description, Business Overview and Total Revenue

6.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)

6.1.4 Boehringer Ingelheim Products Offered

6.1.5 Boehringer Ingelheim Recent Development and Response to COVID-19

6.2 Roche

6.2.1 Roche Corporation Information

- 6.2.2 Roche Description, Business Overview and Total Revenue
- 6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
- 6.2.4 Roche Products Offered
- 6.2.5 Roche Recent Development and Response to COVID-19
- 6.3 FibroGen, Inc.
  - 6.3.1 FibroGen, Inc. Corporation Information
  - 6.3.2 FibroGen, Inc. Description, Business Overview and Total Revenue
  - 6.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.3.4 FibroGen, Inc. Products Offered
  - 6.3.5 FibroGen, Inc. Recent Development and Response to COVID-19
- 6.4 Merck & Co., Inc.
  - 6.4.1 Merck & Co., Inc. Corporation Information
  - 6.4.2 Merck & Co., Inc. Description, Business Overview and Total Revenue
  - 6.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.4.4 Merck & Co., Inc. Products Offered
  - 6.4.5 Merck & Co., Inc. Recent Development and Response to COVID-19
- 6.5 Bristol-Myers Squibb Company
  - 6.5.1 Bristol-Myers Squibb Company Corporation Information
  - 6.5.2 Bristol-Myers Squibb Company Description, Business Overview and Total Revenue
  - 6.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.5.4 Bristol-Myers Squibb Company Products Offered
  - 6.5.5 Bristol-Myers Squibb Company Recent Development and Response to COVID-19
- 6.6 MediciNova, Inc.
  - 6.6.1 MediciNova, Inc. Corporation Information
  - 6.6.2 MediciNova, Inc. Description, Business Overview and Total Revenue
  - 6.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.6.4 MediciNova, Inc. Products Offered
  - 6.6.5 MediciNova, Inc. Recent Development and Response to COVID-19
- 6.7 Genentech, Inc.
  - 6.6.1 Genentech, Inc. Corporation Information
  - 6.6.2 Genentech, Inc. Description, Business Overview and Total Revenue
  - 6.6.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)



- 6.4.4 Genentech, Inc. Products Offered
- 6.7.5 Genentech, Inc. Recent Development and Response to COVID-19
- 6.8 Cipla Inc.
  - 6.8.1 Cipla Inc. Corporation Information
  - 6.8.2 Cipla Inc. Description, Business Overview and Total Revenue
  - 6.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.8.4 Cipla Inc. Products Offered
  - 6.8.5 Cipla Inc. Recent Development and Response to COVID-19
- 6.9 Biogen
  - 6.9.1 Biogen Corporation Information
  - 6.9.2 Biogen Description, Business Overview and Total Revenue
  - 6.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.9.4 Biogen Products Offered
  - 6.9.5 Biogen Recent Development and Response to COVID-19
- 6.10 Galapagos NV
  - 6.10.1 Galapagos NV Corporation Information
  - 6.10.2 Galapagos NV Description, Business Overview and Total Revenue
  - 6.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
  - 6.10.4 Galapagos NV Products Offered
  - 6.10.5 Galapagos NV Recent Development and Response to COVID-19

## **7 PULMONARY FIBROSIS DRUG MANUFACTURING COST ANALYSIS**

- 7.1 Pulmonary Fibrosis Drug Key Raw Materials Analysis
  - 7.1.1 Key Raw Materials
  - 7.1.2 Key Raw Materials Price Trend
  - 7.1.3 Key Suppliers of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
- 7.3 Manufacturing Process Analysis of Pulmonary Fibrosis Drug
- 7.4 Pulmonary Fibrosis Drug Industrial Chain Analysis

## **8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS**

- 8.1 Marketing Channel
- 8.2 Pulmonary Fibrosis Drug Distributors List
- 8.3 Pulmonary Fibrosis Drug Customers

## **9 MARKET DYNAMICS**

- 9.1 Market Trends
- 9.2 Opportunities and Drivers
- 9.3 Challenges
- 9.4 Porter's Five Forces Analysis

## **10 GLOBAL MARKET FORECAST**

- 10.1 Global Pulmonary Fibrosis Drug Market Estimates and Projections by Type
  - 10.1.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Type (2021-2026)
  - 10.1.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Type (2021-2026)
- 10.2 Pulmonary Fibrosis Drug Market Estimates and Projections by Application
  - 10.2.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Application (2021-2026)
  - 10.2.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Application (2021-2026)
- 10.3 Pulmonary Fibrosis Drug Market Estimates and Projections by Region
  - 10.3.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Region (2021-2026)
  - 10.3.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Region (2021-2026)
- 10.4 North America Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
- 10.5 Europe Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
- 10.6 Asia Pacific Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
- 10.7 Latin America Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
- 10.8 Middle East and Africa Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)

## **11 RESEARCH FINDING AND CONCLUSION**

## **12 METHODOLOGY AND DATA SOURCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Author List

## 12.4 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Pulmonary Fibrosis Drug Sales (K Units) Growth Rate Comparison by Type (2015-2026)

Table 2. Global Pulmonary Fibrosis Drug Sales (K Units) Comparison by Application: 2020 VS 2026

Table 3. Global Pulmonary Fibrosis Drug Market Size by Type (K Units) (US\$ Million) (2020 VS 2026)

Table 4. COVID-19 Impact Global Market: (Four Pulmonary Fibrosis Drug Market Size Forecast Scenarios)

Table 5. Opportunities and Trends for Pulmonary Fibrosis Drug Players in the COVID-19 Landscape

Table 6. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 7. Key Regions/Countries Measures against Covid-19 Impact

Table 8. Proposal for Pulmonary Fibrosis Drug Players to Combat Covid-19 Impact

Table 9. Global Key Pulmonary Fibrosis Drug Manufacturers Covered in This Study

Table 10. Global Pulmonary Fibrosis Drug Sales (K Units) by Manufacturers (2015-2020)

Table 11. Global Pulmonary Fibrosis Drug Sales Share by Manufacturers (2015-2020)

Table 12. Global Pulmonary Fibrosis Drug Revenue (Million USD) by Manufacturers (2015-2020)

Table 13. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2015-2020)

Table 14. Global Market Pulmonary Fibrosis Drug Average Price (US\$/Unit) of Key Manufacturers (2015-2020)

Table 15. Manufacturers Pulmonary Fibrosis Drug Sales Sites and Area Served

Table 16. Manufacturers Pulmonary Fibrosis Drug Product Types

Table 17. Global Pulmonary Fibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 18. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Fibrosis Drug as of 2019)

Table 19. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 20. Main Points Interviewed from Key Pulmonary Fibrosis Drug Players

Table 21. Global Pulmonary Fibrosis Drug Sales (K Units) by Region (2015-2020)

Table 22. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2015-2020)

Table 23. Global Pulmonary Fibrosis Drug Revenue (Million US\$) by Region (2015-2020)

Table 24. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2015-2020)

Table 25. North America Pulmonary Fibrosis Drug Sales by Country (2015-2020) (K Units)

Table 26. North America Pulmonary Fibrosis Drug Sales Market Share by Country (2015-2020)

Table 27. North America Pulmonary Fibrosis Drug Revenue by Country (2015-2020) (US\$ Million)

Table 28. North America Pulmonary Fibrosis Drug Revenue Market Share by Country (2015-2020)

Table 29. Europe Pulmonary Fibrosis Drug Sales by Country (2015-2020) (K Units)

Table 30. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2015-2020)

Table 31. Europe Pulmonary Fibrosis Drug Revenue by Country (2015-2020) (US\$ Million)

Table 32. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country (2015-2020)

Table 33. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2015-2020) (K Units)

Table 34. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region (2015-2020)

Table 35. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2015-2020) (US\$ Million)

Table 36. Asia Pacific Pulmonary Fibrosis Drug Revenue Market Share by Region (2015-2020)

Table 37. Latin America Pulmonary Fibrosis Drug Sales by Country (2015-2020) (K Units)

Table 38. Latin America Pulmonary Fibrosis Drug Sales Market Share by Country (2015-2020)

Table 39. Latin America Pulmonary Fibrosis Drug Revenue by Country (2015-2020) (US\$ Million)

Table 40. Latin America Pulmonary Fibrosis Drug Revenue Market Share by Country (2015-2020)

Table 41. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2015-2020) (K Units)

Table 42. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2015-2020)

Table 43. Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country (2015-2020) (US\$ Million)

Table 44. Middle East and Africa Pulmonary Fibrosis Drug Revenue Market Share by Country (2015-2020)

- Table 45. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2015-2020)
- Table 46. Global Pulmonary Fibrosis Drug Sales Share by Type (2015-2020)
- Table 47. Global Pulmonary Fibrosis Drug Revenue (Million US\$) by Type (2015-2020)
- Table 48. Global Pulmonary Fibrosis Drug Revenue Share by Type (2015-2020)
- Table 49. Global Pulmonary Fibrosis Drug Price (US\$/Unit) by Type (2015-2020)
- Table 50. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2015-2020)
- Table 51. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
- Table 52. Global Pulmonary Fibrosis Drug Sales Growth Rate by Application (2015-2020)
- Table 53. Boehringer Ingelheim Pulmonary Fibrosis Drug Corporation Information
- Table 54. Boehringer Ingelheim Description and Business Overview
- Table 55. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 56. Boehringer Ingelheim Main Product
- Table 57. Boehringer Ingelheim Recent Development
- Table 58. Roche Pulmonary Fibrosis Drug Corporation Information
- Table 59. Roche Corporation Information
- Table 60. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 61. Roche Main Product
- Table 62. Roche Recent Development
- Table 63. FibroGen, Inc. Pulmonary Fibrosis Drug Corporation Information
- Table 64. FibroGen, Inc. Corporation Information
- Table 65. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 66. FibroGen, Inc. Main Product
- Table 67. FibroGen, Inc. Recent Development
- Table 68. Merck & Co., Inc. Pulmonary Fibrosis Drug Corporation Information
- Table 69. Merck & Co., Inc. Corporation Information
- Table 70. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 71. Merck & Co., Inc. Main Product
- Table 72. Merck & Co., Inc. Recent Development
- Table 73. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Corporation Information
- Table 74. Bristol-Myers Squibb Company Corporation Information
- Table 75. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

- Table 76. Bristol-Myers Squibb Company Main Product
- Table 77. Bristol-Myers Squibb Company Recent Development
- Table 78. MediciNova, Inc. Pulmonary Fibrosis Drug Corporation Information
- Table 79. MediciNova, Inc. Corporation Information
- Table 80. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 81. MediciNova, Inc. Main Product
- Table 82. MediciNova, Inc. Recent Development
- Table 83. Genentech, Inc. Pulmonary Fibrosis Drug Corporation Information
- Table 84. Genentech, Inc. Corporation Information
- Table 85. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 86. Genentech, Inc. Main Product
- Table 87. Genentech, Inc. Recent Development
- Table 88. Cipla Inc. Pulmonary Fibrosis Drug Corporation Information
- Table 89. Cipla Inc. Corporation Information
- Table 90. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 91. Cipla Inc. Main Product
- Table 92. Cipla Inc. Recent Development
- Table 93. Biogen Pulmonary Fibrosis Drug Corporation Information
- Table 94. Biogen Corporation Information
- Table 95. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 96. Biogen Main Product
- Table 97. Biogen Recent Development
- Table 98. Galapagos NV Pulmonary Fibrosis Drug Corporation Information
- Table 99. Galapagos NV Corporation Information
- Table 100. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 101. Galapagos NV Main Product
- Table 102. Galapagos NV Recent Development
- Table 103. Sales Base and Market Concentration Rate of Raw Material
- Table 104. Key Suppliers of Raw Materials
- Table 105. Pulmonary Fibrosis Drug Distributors List
- Table 106. Pulmonary Fibrosis Drug Customers List
- Table 107. Market Key Trends
- Table 108. Key Opportunities and Drivers: Impact Analysis (2021-2026)
- Table 109. Key Challenges

Table 110. Global Pulmonary Fibrosis Drug Sales (K Units) Forecast by Type (2021-2026)

Table 111. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Type (2021-2026)

Table 112. Global Pulmonary Fibrosis Drug Revenue (Million US\$) Forecast by Type (2021-2026)

Table 113. Global Pulmonary Fibrosis Drug Revenue (Million US\$) Market Share Forecast by Type (2021-2026)

Table 114. Global Pulmonary Fibrosis Drug Sales (K Units) Forecast by Application (2021-2026)

Table 115. Global Pulmonary Fibrosis Drug Revenue (Million US\$) Forecast by Application (2021-2026)

Table 116. Global Pulmonary Fibrosis Drug Sales (K Units) Forecast by Region (2021-2026)

Table 117. Global Pulmonary Fibrosis Drug Sales Market Share Forecast by Region (2021-2026)

Table 118. Global Pulmonary Fibrosis Drug Revenue Forecast by Region (2021-2026) (US\$ Million)

Table 119. Global Pulmonary Fibrosis Drug Revenue Market Share Forecast by Region (2021-2026)

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources



## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of Pulmonary Fibrosis Drug

Figure 2. Global Pulmonary Fibrosis Drug Sales Market Share by Type: 2020 VS 2026

Figure 3. Pirfenidone Product Picture

Figure 4. Nintedanib Product Picture

Figure 5. Global Pulmonary Fibrosis Drug Consumption Market Share by Application: 2020 VS 2026

Figure 6. Hospital

Figure 7. Clinic

Figure 8. Global Pulmonary Fibrosis Drug Market Size 2015-2026 (US\$ Million)

Figure 9. Global Pulmonary Fibrosis Drug Sales Capacity (K Units) (2015-2026)

Figure 10. Global Pulmonary Fibrosis Drug Market Size Market Share by Region: 2020 Versus 2026

Figure 11. Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2020

Figure 12. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2019

Figure 13. The Global 5 and 10 Largest Players: Market Share by Pulmonary Fibrosis Drug Revenue in 2019

Figure 14. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 15. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2015-2020)

Figure 16. Global Pulmonary Fibrosis Drug Sales Market Share by Region in 2019

Figure 17. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2015-2020)

Figure 18. Global Pulmonary Fibrosis Drug Revenue Market Share by Region in 2019

Figure 19. North America Pulmonary Fibrosis Drug Sales Market Share by Country in 2019

Figure 20. North America Pulmonary Fibrosis Drug Revenue Market Share by Country in 2019

Figure 21. U.S. Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 22. U.S. Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 23. Canada Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 24. Canada Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 25. Europe Pulmonary Fibrosis Drug Sales Market Share by Country in 2019

Figure 26. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country in 2019

Figure 27. Germany Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 28. Germany Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 29. France Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 30. France Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 31. U.K. Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 32. U.K. Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 33. Italy Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 34. Italy Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 35. Russia Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 36. Russia Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 37. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region in 2019

Figure 38. Asia Pacific Pulmonary Fibrosis Drug Revenue Market Share by Region in 2019

Figure 39. China Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 40. China Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 41. Japan Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 42. Japan Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 43. South Korea Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 44. South Korea Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 45. India Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 46. India Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 47. Australia Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 48. Australia Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 49. Taiwan Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 50. Taiwan Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 51. Indonesia Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 52. Indonesia Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Million)

Figure 53. Thailand Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 54. Thailand Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 55. Malaysia Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 56. Malaysia Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 57. Philippines Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 58. Philippines Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 59. Vietnam Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 60. Vietnam Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 61. Latin America Pulmonary Fibrosis Drug Sales Market Share by Country in 2019

Figure 62. Latin America Pulmonary Fibrosis Drug Revenue Market Share by Country in 2019

Figure 63. Mexico Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 64. Mexico Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 65. Brazil Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 66. Brazil Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 67. Argentina Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 68. Argentina Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 69. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Country in 2019

Figure 70. Middle East and Africa Pulmonary Fibrosis Drug Revenue Market Share by Country in 2019

Figure 71. Turkey Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 72. Turkey Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 73. Saudi Arabia Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 74. Saudi Arabia Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 75. U.A.E Pulmonary Fibrosis Drug Sales Growth Rate (2015-2020) (K Units)

Figure 76. U.A.E Pulmonary Fibrosis Drug Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 77. Sales Market Share of Pulmonary Fibrosis Drug by Type (2015-2020)

Figure 78. Sales Market Share of Pulmonary Fibrosis Drug by Type in 2019

Figure 79. Revenue Share of Pulmonary Fibrosis Drug by Type (2015-2020)

Figure 80. Revenue Market Share of Pulmonary Fibrosis Drug by Type in 2019

Figure 81. Global Pulmonary Fibrosis Drug Sales Growth by Type (2015-2020) (K Units)

Figure 82. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)

Figure 83. Global Pulmonary Fibrosis Drug Sales Market Share by Application in 2019

Figure 84. Global Revenue Share of Pulmonary Fibrosis Drug by Application (2015-2020)

Figure 85. Global Revenue Share of Pulmonary Fibrosis Drug by Application in 2020

Figure 86. Boehringer Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 87. Roche Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 88. FibroGen, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 89. Merck & Co., Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 90. Bristol-Myers Squibb Company Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 91. MediciNova, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 92. Genentech, Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 93. Cipla Inc. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 94. Biogen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 95. Galapagos NV Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 96. Price Trend of Key Raw Materials

Figure 97. Manufacturing Cost Structure of Pulmonary Fibrosis Drug

Figure 98. Manufacturing Process Analysis of Pulmonary Fibrosis Drug

Figure 99. Pulmonary Fibrosis Drug Industrial Chain Analysis

Figure 100. Channels of Distribution

Figure 101. Distributors Profiles

Figure 102. Porter's Five Forces Analysis

Figure 103. North America Pulmonary Fibrosis Drug Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 104. North America Pulmonary Fibrosis Drug Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 105. Europe Pulmonary Fibrosis Drug Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 106. Europe Pulmonary Fibrosis Drug Revenue (Million US\$) and Growth Rate

Forecast (2021-2026)

Figure 107. Latin America Pulmonary Fibrosis Drug Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 108. Latin America Pulmonary Fibrosis Drug Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 109. Middle East and Africa Pulmonary Fibrosis Drug Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 110. Middle East and Africa Pulmonary Fibrosis Drug Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 111. Asia Pacific Pulmonary Fibrosis Drug Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 112. Asia Pacific Pulmonary Fibrosis Drug Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 113. Bottom-up and Top-down Approaches for This Report

Figure 114. Data Triangulation

Figure 115. Key Executives Interviewed

## I would like to order

Product name: Impact of COVID-19 Outbreak on Pulmonary Fibrosis Drug, Global Market Research Report 2020

Product link: <https://marketpublishers.com/r/I02519761AE0EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I02519761AE0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

